PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Docket No: Q86306

Nobuhiko FUSHIMI, et al.

Appln. No.: Not Yet Assigned

Confirmation No.: Not Yet Assigned

Group Art Unit: Not Yet Assigned

Filed: February 22, 2005

Examiner: Not Yet Assigned

For: PYRAZOLE DERIVATIVES, MEDICINAL COMPOSITION CONTAINING THE SAME, MEDICINAL USE THEREOF, AND INTERMEDIATE FOR PRODUCTION

THEREOF

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §§ 1.97 and 1.98

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, Applicant hereby notifies the U.S. Patent and Trademark Office of the documents which are listed on the attached PTO/SB/08 A & B (modified) form and/or listed herein and which the Examiner may deem material to patentability of the claims of the above-identified application.

One copy of each of the listed documents is submitted herewith, except for the following: U.S. patents and/or U.S. patent publications; and co-pending non-provisional U.S. applications filed after June 30, 2003.

The present Information Disclosure Statement is being filed: (1) No later than three months from the application's filing date; (2) Before the mailing date of the first Office Action on the merits (whichever is later); or (3) Before the mailing date of the first Office Action after

10525197 - GAU: 10525197 - GAU: 10525197 - GAU: 10525197 - GAU: 10525197 - GAU:

INFORMATION DISCLOSURE STATEMENT U.S. Application Not Yet Assigned

filing a request for continued examination (RCE) under §1.114, and therefore, no Statement under 37 C.F.R. § 1.97(e) or fee under 37 C.F.R. § 1.17(p) is required.

The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application. Applicant does not waive any right to take any action that would be appropriate to antedate or otherwise remove any listed document as a competent reference against the claims of the present application.

The USPTO is directed and authorized to charge all required fees, except for the Issue Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any overpayments to said Deposit Account. A duplicate copy of this paper is attached.

Respectfully submitted,

Peter D. Olexy Registration No. 24,513

SUGHRUE MION, PLLC Telephone: (202) 293-7060 Facsimile: (202) 293-7860

WASHINGTON OFFICE 23373
CUSTOMER NUMBER

Date: February 22, 2005

9T01 Rec'd PORPET 92 2 (FAB) 2005

8 m. 6 8		_		9101110	MODIFIED PTO/SB/08 A & B (06-			
Substitute for Form 1449 A & B/PTO			-	plete if Known				
				Application Number	Not Wet Asalghon 5 1 9 7			
INFO	RMATION D	ISCLOS	SURE	Confirmation Number	Not Yet Assigned			
STAT	EMENT BY	APPLIC	CANT	Filing Date	February 22, 2005			
				First Named Inventor	Nobuhiko FUSHIMI			
(us	e as many sheets	as necessa	ry)	Art Unit	Not Yet Assigned			
				Examiner Name	Not Yet Assigned			
Sheet	1	of	1	Attorney Docket Number	O86306			

				PATENT DOCUM	ENTS
		Document N	lumber	Publication Date MM-DD-YYYY	
	Cite No.1	Number	Kind Code ² (if known)		Name of Patentee or Applicant of Cited Docum
		US			

FOREIGN PATENT DOCUMENTS							
Examiner Cite Initials* No.1	Fo	Foreign Patent Document			Name of Patentee or		
	Country Code ³	Number ⁴	Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Applicant of Cited Document	Translation*	
/ESO/		EP	1 338 603	Al	08-27-2003	Ajinomoto Co.	English
/ESO/		EP	1 354 888	A1	10-22-2003	Kissei Pharmaceutical Co., Ltd.	English
/ESO/		EP	1 213 296	A1	06-12-2002	Kissei Pharmaceutical Co., Ltd.	English

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (bouk, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.	Translation ⁶	
/ESO/		Biochemical Society Transactions, 21998, Vol. 26, No. 2, page S180 (1998)		

Examiner Signature	/Eric Olson/	Date Considered	01/02/2008

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

^{*}Applican's unique elimine designation number (optionss). *See Kind Codes of US/TO Patent Documents at www.uspio.gov, MPEP 991.04 or in the comment box of this document. *I Enter Office that is used the document, but the document of the reign of the reign of the Engager must precede the terral number of the patent document. *Kind of Johnson of the William of Managare Transitions and the Code of the Code of the Patent o